Similar articles

• High-level levodopa therapy in Parkinson's disease: five years later.

  Barbeau A. Barbeau A. Trans Am Neurol Assoc. 1974;99:160-3. Trans Am Neurol Assoc. 1974. PMID: 4463526 No abstract available.
• Early combination of dopamine agonist and levodopa in the treatment of Parkinson's disease.

  Rinne UK. Rinne UK. Mt Sinai J Med. 1988 Mar;55(2):138-41. Mt Sinai J Med. 1988. PMID: 3260342 No abstract available.
• Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.

  Lieberman AN, Gopinathan G, Neophytides A, Pasternack P. Lieberman AN, et al. N Y State J Med. 1986 Dec;86(12):655-6. N Y State J Med. 1986. PMID: 3468386 No abstract available.
• Levodopa delivery systems for the treatment of Parkinson's disease: an overview.

  Goole J, Amighi K. Goole J, et al. Int J Pharm. 2009 Oct 1;380(1-2):1-15. doi: 10.1016/j.ijpharm.2009.07.026. Epub 2009 Aug 3. Int J Pharm. 2009. PMID: 19651197 Review.
• Ropinirole therapy for Parkinson's disease.

  Pahwa R, Lyons KE, Hauser RA. Pahwa R, et al. Expert Rev Neurother. 2004 Jul;4(4):581-8. doi: 10.1586/14737175.4.4.581. Expert Rev Neurother. 2004. PMID: 15853577 Review.